Key result
Review of literature data suggests that blocking the PGE2 receptor EP3 reduces atherothrombosis without impacting hemostasis, justifying future phase III trials for myocardial infarction prevention.
Why the study?
Does blocking the receptor EP3 to PGE2 prevent atherothrombosis without increasing bleeding risk?
Population
Mice and humans (literature review on atherothrombosis)
Design
Review
Loading...
EP3 blockade may enable safer atherothrombosis prevention; leaves open phase III confirmation for MI risk reduction.
Does blocking the receptor EP3 to PGE2 prevent atherothrombosis without increasing bleeding risk?
Blocking the EP3 receptor to PGE2 is a promising therapeutic target for preventing atherothrombosis without increasing bleeding risk.
A 2016 study conducted a review in Atherothrombosis. EP3 blockers was evaluated. Review of literature data suggests that blocking the PGE2 receptor EP3 reduces atherothrombosis without impacting hemostasis, justifying future phase III trials for myocardial infarction prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: